| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LACRT |
| Uniprot No | Q9GZZ8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-138aa |
| 氨基酸序列 | EDASSDSTGADPAQEAGTSKPNEEISGPAEPASPPETTTTAQETSAAAVQ GTAKVTSSRQELNPLKSIVEKSILLTEQALAKAGKGMHGGVPGGKQFIEN GSEFAQKLLKKFSLLKPWA |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LACRT(Lacritin)重组蛋白的参考文献示例(内容为模拟虚构，仅供参考)：
1. **标题**：*Expression and Purification of Recombinant Lacritin for Ocular Therapy*
**作者**：Smith J., et al.
**摘要**：研究通过大肠杆菌系统成功表达并纯化重组Lacritin蛋白，证实其具有促进人角膜上皮细胞增殖的活性，为干眼症治疗提供潜在药物原料。
2. **标题**：*Recombinant Lacritin Accelerates Corneal Wound Healing in a Murine Model*
**作者**：Lee H., Zhang R.
**摘要**：在小鼠角膜损伤模型中，局部应用重组Lacritin显著缩短上皮修复时间，证明其在促进角膜伤口愈合中的治疗潜力。
3. **标题**：*Structural and Functional Analysis of Recombinant Lacritin's Tear Film Interaction*
**作者**：Garcia M., et al.
**摘要**：通过X射线晶体学解析重组Lacritin的三维结构，揭示其与泪膜脂层相互作用的分子机制，为优化其稳定性提供理论依据。
4. **标题**：*Recombinant Lacritin as a Therapeutic Agent for Dry Eye Disease: In Vitro and In Vivo Efficacy*
**作者**：Wang Y., et al.
**摘要**：体外实验显示重组Lacritin能增强泪液分泌，动物模型验证其缓解干眼症状的效果，支持其作为新型生物制剂的临床转化前景。
**Background of LACRT Recombinant Protein**
LACRT (lacritin), a secreted glycoprotein encoded by the *LACRT* gene, is predominantly expressed in the lacrimal gland, ocular surface tissues, and tear fluid. It plays a critical role in maintaining ocular surface homeostasis, promoting corneal epithelial cell proliferation, and regulating tear production. Discovered in the early 2000s, lacritin has garnered attention for its therapeutic potential in treating dry eye disease (DED), a prevalent condition characterized by insufficient tear secretion or excessive evaporation.
Structurally, lacritin contains a conserved N-terminal domain rich in leucine residues and a C-terminal region implicated in cell signaling. It binds to syndecan-1. a heparan sulfate proteoglycan on epithelial cells, activating mitogen-activated protein kinase (MAPK) pathways to stimulate cell growth and wound healing. Notably, lacritin levels are reduced in tears of individuals with DED, suggesting its role as a biomarker and therapeutic target.
Recombinant LACRT protein is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, to ensure proper folding and post-translational modifications. Its applications span biomedical research, including in vitro studies of epithelial repair mechanisms, and preclinical models of ocular diseases. Additionally, LACRT-based therapies are under exploration, with formulations like topical eye drops or hydrogels aiming to restore tear film stability and corneal integrity.
Recent studies also highlight lacritin’s anti-inflammatory properties and potential in treating other disorders, such as Sjögren’s syndrome. Despite promising data, challenges remain in optimizing delivery systems and understanding long-term safety. Overall, LACRT recombinant protein represents a promising biologic bridging ocular research and clinical innovation.
×
